BOSTON --(BUSINESS WIRE)--May 11, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, will participate in a fireside chat at the 2026 RBC Capital Markets
-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany - BOSTON --(BUSINESS WIRE)--May 6, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the
– Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 – – Povetacicept program continues rapid advancement: Completed rolling BLA submission for U.S. accelerated approval for povetacicept in IgA nephropathy, following positive Phase 3 interim analysis data; initiated Phase
BOSTON --(BUSINESS WIRE)--Apr. 6, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein- -Approximately 800 more people with CF in the US are
- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically significant and clinically meaningful 49.8% reduction in UPCR versus placebo (P
BOSTON --(BUSINESS WIRE)--Mar. 5, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a
-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting - BOSTON --(BUSINESS WIRE)--Mar. 5, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq:
BOSTON --(BUSINESS WIRE)--Feb. 17, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen’s 46 th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3,
— Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — — Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products
BOSTON --(BUSINESS WIRE)--Jan. 20, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 , after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
BOSTON --(BUSINESS WIRE)--Jan. 11, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 44th annual J.P.
BOSTON --(BUSINESS WIRE)--Dec. 22, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani , Chief Executive Officer and President, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 , at 5:15 p.m.